| Outcome Measures: |
Primary: Change in HbA1c, Change from baseline in Glycosylated Haemoglobin after 26 weeks of treatment, Week 0 to Week 26 | Secondary: Change in FPG(fasting plasma glucose), Change from baseline in FPG after 26 weeks of treatment, Week 0 to Week 26|Proportion of Subjects with HbA1c<7% and HbA1c≤6.5%, Proportion of subjects with HbA1c\<7% and HbA1c≤6.5% after 26 weeks of treatment, Week 0 to Week 26|per-breakfast SMPG, Mean and Within-subject variability of pre-breakfast SMPG after 26 weeks of treatment, Week 0 to Week 26|8-point SMPG profiles, Week 0 to Week 26|Average daily Insulin dose, Average daily Insulin dose after 26 weeks of treatment., Week 0 to Week 26|Proportion of Subjects requiring rescue therapy during treatment, Proportion of subejcts requiring rescue therapy during 26 weeks of treatment, Week 0 to Week 26|Frequency and severity of adverse events, Severity (mild, moderate and severe) is assessed by investigator., Week 0 to Week26 +14 days follow-up|Incidence and rate of Hypoglycemic events, Incidence and rate of of Hypoglycemic events, Week 0 to Week 26+14 days follow-up|Change in weight, Change from baseline in weight after 26weeks of treatment, Week 0 to Week 26|Anti-drug Antibodies, Number of subjects with Positive Anti-drug Antibodies, Week 0 to Week26 + 14 days follow-up|Serum INS068 concentration, To evaluate PK of INS068, Week 0 to Week 26|Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs), Change from baseline in scores of DTSQs after 26 weeks of treatment., Week 0 to Week 26
|
